Patents by Inventor Hanbiao Yang

Hanbiao Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD73 inhibitors and uses thereof
    Patent number: 11591355
    Abstract: The present disclosure provides compounds of Formula (II) wherein R1, R2, R3, R4, R5, W1, W2, W3, X, Y, and A are as described herein. The disclosed compounds modulate CD73 activity. The present disclosure also provides, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: February 28, 2023
    Assignee: Peloton Therapeutics Inc.
    Inventors: Bin Wang, Hanbiao Yang, Karl Bedke, Paul Wehn, James P. Rizzi
  • CD73 INHIBITORS AND USES THEREOF
    Publication number: 20210317150
    Abstract: Compounds that modulate CD73 activity, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity are described herein.
    Type: Application
    Filed: June 4, 2021
    Publication date: October 14, 2021
    Applicant: Peloton Therapeutics, Inc.
    Inventors: Bin Wang, Hanbiao Yang, Karl Bedke, Paul Wehn, James P. Rizzi
  • COMPOSITIONS AND METHODS FOR INHIBITING CD73
    Publication number: 20210253614
    Abstract: Compounds that modulate CD73 activity, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity are described herein.
    Type: Application
    Filed: May 31, 2019
    Publication date: August 19, 2021
    Applicant: Peloton Therapeutics, Inc.
    Inventors: Bin Wang, Hanbiao Yang, Karl Bedke, James P. Rizzi, Heli Huang, Keshi Wang
  • Aromatic compounds and uses thereof
    Patent number: 10807948
    Abstract: Disclosed herein are substituted indane derivatives useful as HIF-2? inhibitors. Pharmaceutical compositions comprising said indane derivatives and methods of using said indane derivatives for treating proliferative diseases, such as renal cell carcinoma and von Hippel-Lindau disease, and other conditions associated with HIF-2? activity are also disclosed.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: October 20, 2020
    Assignee: PELOTON THERAPEUTICS, INC.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
  • ARYL ETHERS AND USES THEREOF
    Publication number: 20200190031
    Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.
    Type: Application
    Filed: February 20, 2020
    Publication date: June 18, 2020
    Applicant: Peloton Therapeutics, Inc.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
  • CD73 INHIBITORS AND USES THEREOF
    Publication number: 20200115404
    Abstract: Compounds that modulate CD73 activity, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity are described herein.
    Type: Application
    Filed: March 29, 2018
    Publication date: April 16, 2020
    Inventors: Bin WANG, Hanbiao YANG, Karl BEDKE, Paul WEHN, James P. RIZZI
  • Aryl ethers and uses thereof
    Patent number: 10597366
    Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: March 24, 2020
    Assignee: Peloton Therapeutics, Inc.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
  • ARYL ETHERS AND USES THEREOF
    Publication number: 20190119214
    Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.
    Type: Application
    Filed: October 18, 2018
    Publication date: April 25, 2019
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
  • Heterocyclic modulators of lipid synthesis and combinations thereof
    Patent number: 10226449
    Abstract: Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by dysregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: March 12, 2019
    Assignee: 3-V Biosciences, Inc.
    Inventors: Timothy Sean Heuer, Johan D. Oslob, Robert S. McDowell, Russell Johnson, Hanbiao Yang, Marc Evanchik, Cristiana A. Zaharia, Haiying Cai, Lily W. Hu, Gregory Duke, Yamini Ohol-Gupta, Marie O'Farrell
  • Heterocyclic modulators of lipid synthesis
    Patent number: 10189822
    Abstract: Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: January 29, 2019
    Assignee: 3-V Biosciences, Inc.
    Inventors: Johan D. Oslob, Robert S. McDowell, Russell Johnson, Hanbiao Yang, Marc Evanchik, Cristiana A. Zaharia, Haiying Cai, Lily W. Hu, Gregory Duke, Yamini Ohol-Gupta, Timothy Sean Heuer, Marie O'Farrell
  • Compositions for Use in Treating Pulmonary Arterial Hypertension
    Publication number: 20190015377
    Abstract: The present disclosure provides methods of treating pulmonary arterial hypertension (PAH) in a subject in need thereof. Compositions for use in these methods are also provided.
    Type: Application
    Filed: July 16, 2018
    Publication date: January 17, 2019
    Applicant: Peloton Therapeutics, Inc.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
  • Substituted pyridines and uses thereof
    Patent number: 10155726
    Abstract: Substituted pyridines that modulate HIF-2a activity, pharmaceutical compositions containing the substituted pyridines, and methods of using these chemical entities for treating proliferative diseases and conditions associated with HIF-2a activity are described herein.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: December 18, 2018
    Assignee: PELOTON THERAPEUTICS, INC.
    Inventors: Paul Wehn, Rui Xu, Hanbiao Yang
  • Aryl ethers and uses thereof
    Patent number: 10144711
    Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: December 4, 2018
    Assignee: PELOTON THERAPEUTICS, INC.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
  • Heterocyclic modulators of lipid synthesis
    Patent number: 10118913
    Abstract: Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: November 6, 2018
    Assignee: 3-V Biosciences, Inc.
    Inventors: Johan D. Oslob, Robert S. McDowell, Russell Johnson, Hanbiao Yang, Marc Evanchik, Cristiana A. Zaharia, Haiying Cai, Lily W. Hu, Allan S. Wagman
  • Heterocyclic modulators of lipid synthesis
    Patent number: 10053450
    Abstract: Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: August 21, 2018
    Assignee: 3-V Biosciences, Inc.
    Inventors: Johan D. Oslob, Robert S. McDowell, Russell Johnson, Hanbiao Yang, Marc Evanchik, Cristiana A. Zaharia, Haiying Cai, Lily W. Hu, Allan S. Wagman
  • HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS
    Publication number: 20180222892
    Abstract: Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds.
    Type: Application
    Filed: March 30, 2018
    Publication date: August 9, 2018
    Inventors: Johan D. OSLOB, Robert S. MCDOWELL, Russell JOHNSON, Hanbiao YANG, Marc EVANCHIK, Cristiana A. ZAHARIA, Haiying CAI, Lily W. HU, Allan S. WAGMAN
  • Benzimidazole derivatives and uses thereof
    Patent number: 10040767
    Abstract: Benzimidazole derivatives of Formula I, that modulate the activity of ACSS2 are disclosed for therapeutic use. The fused imidazole ring of the compounds disclosed has a diarylmethyl or diarylmethanol moiety attached at the 2-position and the as compounds have at least one other substituent at the 5 or 6 position of the benzimidazole. Also disclosed are methods of using the benzimidazole compounds for the treatment of diseases or disorders, such as cancer.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: August 7, 2018
    Assignee: Peloton Therapeutics, Inc.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Hanbiao Yang
  • AROMATIC COMPOUNDS AND USES THEREOF
    Publication number: 20180162807
    Abstract: Aromatic entities that modulate HIF-2? activity, pharmaceutical compositions containing the aromatic entities, and methods of using these chemical entities for treating proliferative diseases and conditions associated with HIF-2? activity are described herein.
    Type: Application
    Filed: March 4, 2016
    Publication date: June 14, 2018
    Inventors: Darryl David DIXON, Jonas GRINA, John A. JOSEY, James P. RIZZI, Stephen T. SCHLACHTER, Eli M. WALLACE, Bin WANG, Paul WEHN, Rui Xu, Hanbiao YANG
  • ARYL ETHERS AND USES THEREOF
    Publication number: 20180155279
    Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.
    Type: Application
    Filed: November 7, 2017
    Publication date: June 7, 2018
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
  • Aryl ethers and uses thereof
    Patent number: RE49948
    Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.
    Type: Grant
    Filed: February 3, 2022
    Date of Patent: April 30, 2024
    Assignee: Peloton Therapeutics, Inc.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang